Anagrelide-Induced Supraventricular Tachycardia: A Case Report

Area of Science:

• Cardiology
• Pharmacology

Background:

• Anagrelide inhibits phosphodiesterase-3 (PDE-3), suppressing megakaryocytes for essential thrombocythemia treatment.
• Anagrelide can induce cardiovascular effects, though side effects like arrhythmias are rare.

Observation:

• A 71-year-old female presented with sudden chest pain while on anagrelide and aspirin.
• She developed supraventricular tachycardia (SVT) with aberrancy, responsive to beta-blockers.

Findings:

• Cardiac imaging (X-ray, CTA, echocardiogram) revealed no abnormalities.
• The patient's SVT was potentially linked to anagrelide due to the absence of other cardiac findings.

Implications:

• This case suggests anagrelide may be an underrecognized cause of cardiac arrhythmias.
• Clinicians should consider anagrelide's potential cardiovascular effects in patients presenting with unexplained arrhythmias.